NCT00387569View on ClinicalTrials.gov

Study Evaluating Safety & Immunogenicity of rLP2086 Vaccine in Healthy Toddlers

PHASE1CompletedINTERVENTIONAL
Enrollment

99

Participants

Timeline

Start Date

October 31, 2006

Primary Completion Date

March 31, 2008

Study Completion Date

March 31, 2008

Conditions
Healthy
Interventions
BIOLOGICAL

MnB vaccine rLP8026

MnB vaccine at 20ug dose (0,1,6 months) or control (Hepatitis A vaccine, placebo, Hepatitis A vaccine at 0,1,6 months, respectively)

BIOLOGICAL

MnB vaccine rLP8026

MnB vaccine at 60ug dose (0,1,6 months) or control (Hepatitis A vaccine, placebo, Hepatitis A vaccine at 0,1,6 months, respectively)

BIOLOGICAL

MnB vaccine rLP8026

MnB vaccine at 200ug dose (0,1,6 months) or control (Hepatitis A vaccine, placebo, Hepatitis A vaccine at 0,1,6 months, respectively)

Trial Locations (1)

6840

Perth

All Listed Sponsors
lead

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

NCT00387569 - Study Evaluating Safety & Immunogenicity of rLP2086 Vaccine in Healthy Toddlers | Biotech Hunter | Biotech Hunter